Article
Rethinking ovarian cancer III: the past decade and future directions.
Nature reviews. Cancer - 1 Jun 2026
Balkwill Frances R, Laumont Céline M, Burdett Nikki, Le Saux Olivia, Garsed Dale W, Grither Whitney R, Nijhuis Anke M, Recouvreux Maria S, Kang Ziqi, Zhang Rugang, Chiappinelli Katherine B, Lee Jason S, Laniti Denarda Dangaj, McNeish Iain, Ahmed Ahmed A, Rottapel Robert, Conejo-Garcia Jose R, Odunsi Kunle, Pharoah Paul D P, Zamarin Dmitriy, Ishak Charles A, Fotopoulou Christina, Buckanovich Ronald J, Labidi-Galy Intidhar, Brenton James D, Lengyel Ernst, Cook David P, George Sophia H L, Lheureux Stephanie, Drapkin Ronny, Nephew Kenneth P, Adams Sarah, Pathania Shailja, Nelson Brad H, Färkkilä Anniina, Fuh Katherine, Neel Benjamin G, Bowtell David D
Abstract excerpt
Approximately 80% of deaths from ovarian cancer are due to high-grade serous carcinoma (HGSC), which has the highest proportion of BRCA1 or BRCA2 (BRCA1/BRCA2) mutations of any cancer type and is a highly chromosomally unstable disease. Despite the introduction of targeted therapies benefitting some patients with HGSC as well as surgical advances, only 50% of patients will survive more than 5 years, and just 30%...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.